The blue pill (sildenafil) and its descendants: an overview

Open access

Abstract

An increasing number of men around the world suffer from erectile dysfunction (ED). Indeed, according to the sexuality study conducted by Professor Izdebski, 1 out of 10 men in Poland suffers from ED. The problem is found among men of any age, however, 60% of all patients are between 40 and 60 years old, thus in their prime, and who still want to fully enjoy life. Not only do the effects of ED affect a man, but they have influence on his relationship and partner as well. In spite of a growing awareness within society, the problem remains perceived as embarrassing, which leads patients to treat themselves on their own, delaying a visit to their doctors. Meanwhile, in many cases, ED may be the first symptom of more serious diseases, such as diabetes, or result from the sideeffects of applied drugs. A breakthrough in the oral medication treatment of ED was observed when a new phosphodiesterase type 5 inhibitor (PDE-5-inhibitor) - sildenafil citrate (Viagra®) - was introduced. Nowadays, 5 active substances from this group are being applied. The current medical guidelines recommend PDE-5 inhibitors as the firstline therapy for most men with ED, irrespective of the cause and severity of the disease. Recently, sildenafil at the dose of 25 mg came into the market without prescription. This paper presents an overview and update of the PDE-5 inhibitors.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA.1993;270(1):83-90.

  • 2. Gong B Ma M Xie W Yang X Huang Y Sun T et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(10):1731-40. doi:

    • Crossref
    • Export Citation
  • 3. Izdebski Z. Seksualność Polakow na początku XXI wieku. Studium badawcze. Krakow: Wyd. UJ; 2012:287-92.

  • 4. Szurgociński A. Zaburzenia erekcji w Polsce. Grodzisk Mazowiecki: Vedi Clinic;2016.

  • 5. Moreland RB Hsieh G Nakane M Brioni JD. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther. 2001;296(2):225-34.

  • 6. Rabijewski M. Zaburzenia erekcji - etiologia i leczenie. Przegl. Urol. 2006;4(38):46.

  • 7. Izdebski Z. Obawy i trudności w życiu seksualnym. Rocz Lubus. 2006;32(2):13-8.

  • 8. Dęmbe K Jasik M Stawicki S Karnafel W. Patogeneza i częstość zaburzeń erekcji u chorych na cukrzycę. Seksuol Pol. 2004;2 (2):51-54.

  • 9. Hatzimouratidis K Amar E Eardley I Giuliano F Hatzichristou D Montorsi F et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804-14. doi:

    • Crossref
    • Export Citation
  • 10. Ferguson JE Carson CC. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. Arab J Urol. 2013;11(3):222-229. doi:

    • Crossref
    • Export Citation
  • 11. Woroń J Kostka-Trąbka E. Zaburzenia erekcji jako wynik niepożądanego działania lekow. Seksuol Pol. 2005;3:18-22.

  • 12. Rew KT Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820-827.

  • 13. Rosen RC. Psychogenic erectile dysfunction. Classification and management. Urol Clin North Am. 2001;28(2):269-78.

  • 14. Reisman Y Hind A Varaneckas A Motil I. Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA)-A Second Generation Technology. Int J Impot Res. 2015;27(3):108-12. doi:

    • Crossref
    • Export Citation
  • 15. Snyder PJ Ellenberg SS Farrar JT. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-24. doi:

    • Crossref
    • Export Citation
  • 16. Anaissie J Hellstrom WJ. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. Res Rep Urol. 2016;8:123.

  • 17. Altwein JE Keuler FU. Oral treatment of erectile dysfunction with apomorphine SL. Urol Int. 2001;67(4):257-63.

  • 18. Rabijewski M Papierska L. Pathogenesis and treatment of erectile dysfunction. Ger Pol. 2007;1:203-8.

  • 19. Goldstein I Lue TF Padma-Nathan H Rosen RC Steers WD Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397-1404.

  • 20. McCullough AR. Four-year review of sildenafil citrate. Reviews in Urology. 2002;4Suppl 3:26.

  • 21. Hackett G Kell P Ralph D Dean J Price D Speakman Metal. British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med. 2008;5:1841-65.

  • 22. Lew-Starowicz Z. Inhibitory fosfodiesterazy typu 5 - podobieństwa i rożnice. Seksuol Pol. 2003;(2):79-82.

  • 23. Liu Y. The tale of Viagra patents: comparative studies of the global challenges in China and other countries. 2013;18:523-33.

  • 24. Huang SA Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T. 2013;38(7):407-19.

  • 25. Jiann BP. Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. Urol Sci. 2016;27 (2):66-70.

  • 26. Cho MC Paick JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014;10:341-54. doi:

    • Crossref
    • Export Citation
  • 27. Zhao C Kim SW Yang DJ Kim JJ Park NC Lee SW et al. Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter Randomized Double- Blind Placebo-Controlled Trial. Eur Urol. 2011;60(2):380-7. doi:

    • Crossref
    • Export Citation
  • 28. Kim TE Kim BH Kim JR Lim KS Hong JH Kim KP et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2009;68(1):43-6. doi:

    • Crossref
    • Export Citation
  • 29. http://www.mims.com/malaysia/drug/info/zydena/

  • 30. LevitraR (vardenafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London GB. 2009. Last update: 06/04/2017

  • 31. CialisR (tadalafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London GB. 2007. Last update: 15/06/2016.

  • 32. ViagraR (sildenafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London GB. 2008. Last update: 12/07/2016

  • 33. SpedraR (avanafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London GB. 2013. Last update: 10/03/2015.

  • 34. Stendra (avanafil) prescribing information. Mountainview Calif.: Vivus Inc.; April 2012.

  • 35. Staxyn (vardenafil ODT) prescribing information. Wayne NJ.; Bayer Healthcare/GlaxoSmithKline; revised April 2011.

  • 36. Warrington JS Shader RI von Moltke LL Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000;28(4):392-7.

  • 37. Jetter A Kinzig‐Schippers M Walchner‐Bonjean M Hering U Bulitta J Schreiner P et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 2002;71(1):21-9.

  • 38. Young JM. Vardenafil. Expert. Opin. Investig. Drugs 2002;11:1487-96.

  • 39. Gresser U Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil vardenafil and tadalafil - review of the literature. Eur. J. Med. Res. 2002;7:435-46.

  • 40. Kloner RA Mullin SH Shook T et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J. Urol. 2003;170 (2):S46-50.

  • 41. Swearingen D Nehra A Morelos S Peterson CA. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context. 2013;26:212248. doi:

    • Crossref
    • Export Citation
  • 42. Giuliano F Jackson G Montorsi F Martin-Morales A Raillard P et al. Safety of sildenafi l citrate: review of 67 double-blind placebocontrolled trials and the postmarketing safety database. Int J Clin Pract. 2010;64(2):240-55.

  • 43. Kuczerowski R. Nowe możliwości leczenia zaburzeń erekcji u mężczyzn z cukrzycą typu 2. Diabetologia Kliniczna 2015;4 (4):158-62. doi:

    • Crossref
    • Export Citation
Search
Journal information
Impact Factor


CiteScore 2018: 0.32

SCImago Journal Rank (SJR) 2018: 0.154
Source Normalized Impact per Paper (SNIP) 2018: 0.285

Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 396 197 13
PDF Downloads 195 117 3